The present disclosure relates to noninvasive methods, devices, and systems for measuring various blood constituents or analytes, such as glucose. In an embodiment, a light source comprises LEDs and super-luminescent LEDs. The light source emits light at at least wavelengths of about 1610 nm, about 1640 nm, and about 1665 nm. In an embodiment, the detector comprises a plurality of photodetectors arranged in a special geometry comprising one of a substantially linear substantially equal spaced geometry, a substantially linear substantially non-equal spaced geometry, and a substantially grid geometry.

The present invention relates to a myocardial spectrometer probe, comprising: at least two separate light guides (120A, 120B), insertable in a tissue, wherein a first light guide (120A, 120B) is arranged to deliver light and a second light guide (120A, 120B) is arranged to collect light, and wherein the first light guide (120A, 120B) and the second light guide (120A, 120B) are arranged distinct to each other.

A vision screening device for administering vision screening tests, and in particular a color vision screening test, to a patient is described herein. The vision screening device may include associated methods and systems configured to perform the operations of the vision screening tests. The device may include a first radiation source configured to generate color stimuli, a second radiation source separate from the first radiation source configured to emit near-infrared radiation, and a sensor configured to capture the near-infrared radiation emitted by the second radiation source, and reflected by an eye of a patient. The device may also be configured to cause color stimulus to be displayed to the patient, and determine measurement(s) of the eye of the patient in response to the color stimulus. The device may be further configured to analyze the measurements to generate a recommendation and/or diagnosis associated with the vision of the patient. The device may also be configured to display the recommendation and/or the measurements, along with additional screening data, to an operator conducting the vision test.

This disclosure provides a method for imaging lymph nodes and lymphatic vessels without a contrast agent. The method includes providing, using an optical source, an infrared illumination to a region of a subject having at least one lymphatic component, detecting a reflected portion of the infrared illumination directly reflected from the region using a sensor positioned thereabout, and generating at least one image indicative of the at least one lymphatic component in the subject using the reflected portion of the infrared illumination.

An integrated optical system includes a wavelength tunable optical source and a photonic integrated circuit (PIC). The PIC includes a set of spatial waveguide switches having an input optically coupled to the wavelength tunable optical source and a plurality of outputs. The PIC also includes an optical emitter having a plurality of inputs, each being coupled to a respective one of the plurality of outputs of the set of spatial waveguide switches, the optical emitter configured to produce at an output an optical beam having a wavelength dependent emission direction that changes as light is switched by the set of spatial waveguide switches such that the optical beam may be steered in two dimensions.

The present invention relates to a device (100) for determining a vital sign of a subject by use of PPG. The device comprises a processing unit (110) configured to obtain multiple first detection signals derived from electromagnetic radiation (90) from multiple measurement spots (30) on a skin region (12) of the subject illuminated by one or more illumination spots (20), wherein the electromagnetic radiation (90) enters the skin region (12) at the one or more illumination spots (20) and exits the skin region (12) at the multiple measurement spots (30). The processing unit (110) further obtains 3D image information (130) of the skin region (12) which allows determining the actual spot distance (15) between the measurements spots (30) and an illumination spot (20), respectively. This information can be used to interpret the PPG signal more precisely as without having the 3D image information only a projected distance can be determined if the skin surface is tilted. Additionally, this allows averaging PPG signals derived from a homogenous skin area to improve PPG signal strength and reduce noise. A system (500) comprising such a device and a corresponding method are further described.

A system includes: a light source that emits pulsed light that illuminates a user's head portion; a photodetector that detects at least part of pulsed light returning from the head portion and that outputs one or more signals corresponding to an intensity of the at least part; electrical circuitry; and a memory that stores an emotion model indicating a relationship between the one or more signals and emotions. Based on a change in the one or more signals, the electrical circuitry selects an emotion by referring to the model. The one or more signals include a first signal corresponding to an intensity of first part of the reflection pulsed light and a second signal corresponding to an intensity of second part of the reflection pulsed light. The first part includes part before a falling period is started; and the second part includes at least part in the falling period.

A non-invasive detection method and device, and a wearable apparatus for tissue element are provided. The method includes: acquiring, for a detected site of a detected object, a second light intensity measurement value for each predetermined wavelength of at least one predetermined wavelength at a measurement distance, and/or a second light intensity reference value for each predetermined wavelength of at least one predetermined wavelength at a reference distance, wherein the measurement distance is a source-detection distance corresponding to the first light intensity measurement value, and the reference distance is a source-detection distance corresponding to the first light intensity reference value; and determining a concentration of a tissue element to be detected according to the second light intensity measurement value of each predetermined wavelength and/or the second light intensity reference value for each predetermined wavelength.

An adjustable measurement device is described that may include a housing, a power supply, a processor, a communication device, an elastic coupling member, a physiological sensor, and/or a clamp. The housing may be configured to attach to a wearable band that is wearable by a subject. The housing may include a chamber within the housing. The power supply, the processor, the communication device, the elastic coupling member, and or the physiological sensor may be disposed within the chamber. The elastic coupling member may couple the physiological sensor to the housing. A force exerted by the elastic coupling member on the physiological sensor may be in a direction through an opening towards a body part of a subject. As the subject wears the wearable band and the housing is coupled to the wearable band, the physiological sensor may be adjacent to or contact the subject.

The concentration of substance in blood is measured non-invasively, with high accuracy and with simple configuration. Laser light 100 generated by a light source 10 is locally irradiated on the body epithelium F of a subject, and the resulting diffused reflected light 200 is detected by a light detector 40. The laser light 100 has a wavelength of 9.26 μm. The laser light 100 is generated by converting and amplifying pulsed excitation light 101 from an excitation light source 11 to a long wavelength. A plate-shaped window 300 that is transparent to mid-infrared light is brought in close contact with the body epithelium F. The glucose concentration in interstitial fluid can be calculated using normalized light intensity calculated from a signal ratio of signals from a monitoring light detector 16 and light detector 40.